LEADER 03339nam  2200649Ia 450 
001 9910450418203321
005 20200520144314.0
010   $a1-281-74404-2
010   $a9786611744045
010   $a1-4237-9009-X
010   $a92-4-068058-6
024 3 $z9789241546942
035   $a(CKB)1000000000247153
035   $a(EBL)284772
035   $a(OCoLC)476035299
035   $a(SSID)ssj0000166545
035   $a(PQKBManifestationID)11924566
035   $a(PQKBTitleCode)TC0000166545
035   $a(PQKBWorkID)10145944
035   $a(PQKB)11452961
035   $a(MiAaPQ)EBC284772
035   $a(Au-PeEL)EBL284772
035   $a(CaPaEBR)ebr10137828
035   $a(CaONFJC)MIL174404
035   $a(EXLCZ)991000000000247153
100   $a20060525d2006      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aGuidelines for the treatment of malaria$b[electronic resource] /$fWorld Health Organization
210   $aGeneva $cWorld Health Organization$dc2006
215   $a1 online resource (266 p.)
300   $aDescription based upon print version of record.
311   $a92-4-154694-8 
320   $aIncludes bibliographical references and index.
327   $aPreliminaries; Contents; 1 Introduction; 2 The clinical disease; 3 Treatment objectives; 4 Diagnosis of malaria; 5 Resistance to antimalarial medicines; 6 Antimalarial treatment policy; 7 Treatment of uncomplicated P falciparum malaria; 8 Treatment of severe falciparum malaria; 9 Treatment of malaria caused by P vivax P ovale or P malariae; 10 Mixed malaria infections; 11 Complex emergencies and epidemics; Annex 1. The guidelines development process; Annex 2. Adaptation of WHO malaria treatment guidelines for use in countries; Annex 3. Pharmacology of antimalarial drugs
327   $aAnnex 4. Antimalarials and malaria transmissionAnnex 5. Malaria diagnosis; Annex 6. Resistance to antimalarials; Annex 7. Uncomplicated P. falciparum malaria; Annex 8. Malaria treatment and HIV/AIDS; Annex 9. Treatment of severe P. falciparum malaria; Annex 10. Treatment of P. vivax, P. ovale and P. malariae infections; Index
330   $aMalaria is an important cause of death and illness in children and adults in tropical countries. Mortality, currently estimated at over a million people per year, has risen in recent years, probably due to increasing resistance to antimalarial medicines. Malaria control requires an integrated approach comprising prevention including vector control and treatment with effective antimalarials.The affordable and widely available antimalarial chloroquine which was in the past a mainstay of malaria control is now ineffective in most falciparum malaria endemic areas, and resistance to sulfadoxine-pyr
606   $aMalaria$xChemotherapy
606   $aAntimalarials
606   $aMalaria$xDiagnosis
608   $aElectronic books.
615  0$aMalaria$xChemotherapy.
615  0$aAntimalarials.
615  0$aMalaria$xDiagnosis.
676   $a616.9/36206
676   $a616.9362
712 02$aWorld Health Organization.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910450418203321
996   $aGuidelines for the treatment of malaria$91917966
997   $aUNINA